TABLE 1.
Baseline Characteristics
| SMTM (n = 104) | CMTM (n = 180) | PGxMTM (n = 58) | P Value | |
|---|---|---|---|---|
| Continuous variables, mean (± SD) | ||||
| Number of current conditions | 6.15 (2.21) | 6.61 (2.59) | 6.52 (2.80) | 0.34 |
| Number of active medications | 11.16 (3.79) | 11.49 (4.32) | 11.47 (4.13) | 0.80 |
| Number of ADRsa | 0.44 (0.76) | 0.47 (0.85) | 0.76 (1.17) | 0.06 |
| Age, years | 75.06 (7.38) | 75.16 (8.27) | 74.17 (6.34) | 0.69 |
| Categorical variables, n (%) | ||||
| Gender (female) | 50 (48.1) | 79 (43.9) | 17 (29.3) | 0.06 |
| Therapeutic classes of active medicationsb | ||||
| Hypertension | 95 (91.3) | 166 (92.2) | 55 (94.8) | 0.72 |
| Lipid disorder | 79 (76.0) | 127 (70.6) | 46 (79.3) | 0.34 |
| Nutrition: vitamins and minerals | 80 (76.9) | 124 (68.9) | 45 (77.6) | 0.23 |
| Coagulation disorder | 60 (57.7) | 118 (65.6) | 39 (67.2) | 0.33 |
| Antidiabetic agents | 47 (45.2) | 84 (46.7) | 20 (34.5) | 0.26 |
| Antacid/antiulcer | 44 (42.3) | 78 (43.3) | 29 (50.0) | 0.61 |
| Psychiatry | 41 (39.4) | 76 (42.2) | 27 (46.6) | 0.68 |
| Cardiovascular, NCE | 31 (29.8) | 70 (38.9) | 19 (32.8) | 0.28 |
| Genitourinary disorder | 36 (34.6) | 58 (32.2) | 21 (36.2) | 0.83 |
| Asthma/COPD | 26 (25.0) | 53 (29.4) | 18 (31.0) | 0.64 |
| Allergy/cough/cold | 24 (23.1) | 44 (24.4) | 20 (34.5) | 0.24 |
| Thyroid disorder | 24 (23.1) | 49 (27.2) | 9 (15.5) | 0.19 |
| Pain medication, opioids | 18 (17.3) | 48 (26.7) | 14 (24.1) | 0.20 |
| GI, NCE | 24 (23.1) | 39 (21.7) | 12 (20.7) | 0.93 |
| Seizure | 18 (17.3) | 39 (21.7) | 15 (25.9) | 0.42 |
| Pain, anti-inflammatory | 19 (18.3) | 41 (22.8) | 8 (13.8) | 0.29 |
| Pain, non-narcotic, NCE | 19 (18.3) | 25 (13.9) | 8 (13.8) | 0.58 |
| Corticosteroids | 12 (11.5) | 25 (13.9) | 6 (10.3) | 0.72 |
| Hematopoietic therapy | 12 (11.5) | 25 (13.9) | 5 (8.6) | 0.55 |
| Antiplatelet agents | 13 (12.5) | 18 (10.0) | 8 (13.8) | 0.67 |
| Eye/ear disease | 8 (7.7) | 16 (8.9) | 8 (13.8) | 0.42 |
| Gout | 5 (4.8) | 15 (8.3) | 6 (10.3) | 0.38 |
| Osteoporosis | 8 (7.7) | 12 (6.7) | 4 (6.9) | 0.95 |
| Arrhythmia | 6 (5.8) | 14 (7.8) | 3 (5.2) | 0.71 |
| Skeletomuscular disorder | 3 (2.9) | 13 (7.2) | 3 (5.2) | 0.30 |
aADRs reported or captured on the date of the initial MTM session.
bTherapeutic class based on the drug class code provided by the MTM. Summary of therapeutic classes that was used in more than 5% of participating patients.
ADRs = adverse drug reactions; CDST = clinical decision support tool; CMTM = MTM enhanced by the CDST software without pharmacogenetic information;
COPD = chronic obstructive pulmonary disease; GI = gastrointestinal; MTM = medication therapy management; NCE = not classified elsewhere; PGx = pharmacogenetics;
PGxMTM = MTM supported by PGx information and CDST; SD = standard deviation; SMTM = standard MTM.